<?xml version="1.0"?>
<rss version="2.0">
	<channel>
		<title>Drug News in Anti-Infective area.</title>
		<link>http://www.lifescience-online.com/</link>
		<description>News Feed Powered by Lifescience-online.com</description>
		<language>en-us</language>
		<pubDate>Wed, 08 Feb 2012 03:59:24 +0100</pubDate>
		<lastBuildDate>Wed, 08 Feb 2012 03:59:24 +0100</lastBuildDate>
		<category>News</category>		

		<image>
			<title>Lifescience-online</title>
			<url>http://rss.lifescience-online.com/images/logo.gif</url>
			<link>http://www.lifescience-online.com/</link>
			<width></width>
			<height></height>
			<description>Lifescience-online</description>
		</image>

		<item>
			<title>Idenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide Inhibitor, IDX184</title>
			<link>http://www.lifescience-online.com/Idenix_Announces_Removal_of_the_Partial_Clinical_H,30795.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/1.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Anti-Infective</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/idenix_pharmaceuticals,5826.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>IDENIX PHARMACEUTICALS INC</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/IDX-184,3878.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>IDX-184</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Thu, 02 Feb 2012 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>Gilead Initiates Phase 2 Clinical Trial Evaluating GS-7340, A Low-Dose Novel Prodrug of Tenofovir for the Treatment of HIV</title>
			<link>http://www.lifescience-online.com/Gilead_Initiates_Phase_2_Clinical_Trial_Evaluating,30753.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/2.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Anti-Infective</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/gilead_sciences,692.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>GILEAD SCIENCES INC</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/GS-7340,26369.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>GS-7340</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Tue, 24 Jan 2012 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>NovaBay Prepares to Launch Global Phase 2b Ophthalmic Study of NVC-422</title>
			<link>http://www.lifescience-online.com/NovaBay_Prepares_to_Launch_Global_Phase_2b_Ophthal,30698.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/2.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Anti-Infective</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/novabay_pharmaceuticals,6270.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>NovaBay Pharmaceuticals Inc</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/NVC-422,5964.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>NVC-422</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Sun, 22 Jan 2012 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>B.Braun Medical Becomes the First to Deliver FDA-Approved 2g Cefazolin</title>
			<link>http://www.lifescience-online.com/B_Braun_Medical_Becomes_the_First_to_Deliver_FDA_A,30697.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/2.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Anti-Infective</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/bbraun,7122.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>BBRAUN</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/CEFAZOLIN_SODIUM,11200.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>CEFAZOLIN SODIUM</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Sun, 22 Jan 2012 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>Trius Earns $5 Million Milestone Payment From Bayer for Successful Completion of First Phase 3 Trial of Tedizolid</title>
			<link>http://www.lifescience-online.com/Trius_Earns__5_Million_Milestone_Payment_From_Baye,30691.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/1.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Anti-Infective</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/bayer_healthcare,5151.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>BAYER HEALTHCARE AG</u></font></a><br /><a href='http://www.lifescience-online.com/trius_therapeutics,9917.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>Trius Therapeutics Inc</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/TEDIZOLID_PHOSPHATE,22388.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>TEDIZOLID PHOSPHATE</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Sun, 22 Jan 2012 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>PolyMedix Defensin-Mimetic Antimicrobial Compounds Show Activity Against Oral Candida Fungus and Malaria</title>
			<link>http://www.lifescience-online.com/PolyMedix_Defensin_Mimetic_Antimicrobial_Compounds,30668.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/0.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Anti-Infective</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/polymedix,6478.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>POLYMEDIX INC</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/ANTIMALARIALS,1913.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>ANTIMALARIALS</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Thu, 19 Jan 2012 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>FDA Lifts Hold on Insmed Incorporated (INSM)&#039;s Lung Disease Drug</title>
			<link>http://www.lifescience-online.com/FDA_Lifts_Hold_on_Insmed_Incorporated__INSM__s_Lun,30708.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/0.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Anti-Infective</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/insmed,771.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>INSMED INC</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/LIPOSOMAL_AMIKACIN_FOR_INHALATION,8581.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>LIPOSOMAL AMIKACIN FOR INHALATION</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Thu, 19 Jan 2012 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>Ferrer Internacional Initiates Phase III Clinical Studies for Novel Antibacterial Compound, Ozenoxacin, in Development as a Topical Treatment for Impetigo and Other Infectious Dermatological Conditions</title>
			<link>http://www.lifescience-online.com/Ferrer_Internacional_Initiates_Phase_III_Clinical_,30685.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/1.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Dermatology</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/grupo_ferrer_internacional,9744.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>GRUPO FERRER INTERNACIONAL</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/T-3912,8571.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>T-3912</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Wed, 18 Jan 2012 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

	</channel>
</rss>
